Ipsen, a global biopharmaceutical company, announced it has joined the Biotechnology Innovation Organization (BIO), the largest association of biotechnology companies, academic institutions and biotech centers around the world, and a leader in biotech innovation for over a quarter of a century.
As a member of this global community, Ipsen will be among a network of member industry peers across the life sciences ecosystem to improve the lives of patients and propel both the company and industry into a new era.
Aligned with BIO’s strategic focus on enriching the industry with networking, partnering and education opportunities, Ipsen has placed external innovation and partnerships at the forefront of its growth strategy. Ipsen recently announced the consolidation of its North American business, creating a fully integrated presence, in its new global hub in Cambridge’s Kendall Square—the most innovative square mile in the world, with hundreds of biopharma, venture capital and start-up companies.
In addition to membership with BIO, Ipsen also holds longstanding relationships with a number of associations, including Pharmaceutical Research and Manufacturers of America (PhRMA), the National Pharmaceutical Council (NPC), Massachusetts Biotechnology Council, BioNJ, Innovative Medicines Canada, and the Organization for International Investment. Additionally, Ipsen Group is a member of both the European Federation of Pharmaceutical Industries and Associations and the International Federation of Pharmaceutical Manufacturers and Associations.
Headquartered in Paris (France), Ipsen is a global biopharmaceutical company focused on innovation and specialty care. The group develops and commercializes innovative medicines in three key therapeutic areas – Oncology, Neurosciences and Rare Diseases. Ipsen’s R&D is focused on its innovative and differentiated technological platforms located in the heart of the leading biotechnological and life sciences hubs (Paris-Saclay, France; Oxford, UK; Cambridge, US).